New breast cancer susceptibility gene
"....XRCC2 may also provide a new target for chemotherapy. "A type of drug
called a PARP inhibitor appears to kill tumor cells that have gene
mutations in a particular DNA repair pathway. XRCC2 is in this pathway,
as are BRCA1 and BRCA2. It's reasonably likely that a breast cancer
patient who has a mutation in XRCC2 will respond well to treatment with
PARP inhibitors," said Tavtigian......."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.